摘要
目的研究分析程序性细胞死亡蛋白1(programmed death-1,PD-1)抑制剂治疗晚期肺癌免疫相关不良反应中免疫检查点抑制剂相关肺炎(immune checkpoint inhibitor-related pneumonitis,ICIP)的发生率及危险因素。方法回顾性分析2021年5月~2023年2月在哈尔滨医科大学附属第一医院接受PD-1抑制剂治疗的晚期肺癌患者69例,其中51例接受化疗联合PD-1抑制剂,18例单药PD-1抑制剂治疗,收集患者临床资料信息,包括年龄、性别、美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)评分、肝肾功、血常规、既往合并肺气肿或和间质性肺改变、放疗史、化疗史、预后情况并进行随访,研究分析ICIP的发生率,分析可能导致ICIP发生的危险因素。结果PD-1抑制剂不良反应ICIP发生率为5.8%(4/69),发生ICIP的4例患者均为男性且均有放疗史(P<0.05)。结论PD-1抑制剂在治疗晚期肺癌中不良反应ICIP发生率低;男性且有放疗史可能为ICIP的危险因素。
Objective To study the incidence rate and risk factors of immune checkpoint inhibitor-related pneumonitis(ICIP)in the treatment of advanced lung cancer with programmed death-1(PD-1)inhibitors.Methods A retrospective analysis was conducted on 69 patients with advanced lung cancer who received PD-1 inhibitor treatment in the First Affiliated Hospital of Harbin Medical University from May 2021 to February 2023.Among them,51 patients received chemotherapy combined with PD-1 inhibitors and 18 patients only received PD-1 inhibitor treatment.Clinical data of patients including age,gender,Eastern Cooperative Oncology Group(ECOG)score,liver and kidney function,routine blood test,previous coexisting emphysema or interstitial lung changes,radiotherapy history,chemotherapy history,prognosis were collected,and follow-up was conducted,the incidence rate of ICIP in these patients was analyzed,and potential risk factors that might lead to ICIP through clinical data were also analyzed.Results The incidence rate of ICIP in advanced lung cancer patients treatment with PD-1 inhibitor was 5.8%(4/69).Four patients with ICIP were male and had a history of radiotherapy(P<0.05).Conclusion PD-1 inhibitor has a low incidence rate of ICIP in the treatment of advanced lung cancer.Men with a history of radiation therapy may be risk factors for ICIP.
作者
赵登科
丁宇杉
温垚
赵明格
韩卓言
卫彦霖
孙瑜
高健
ZHAO Deng-ke;DING Yu-shan;WEN Yao;ZHAO Ming-ge;HAN Zhuo-yan;WEI Yan-lin;SUN Yu;GAO Jian(Department of Respiratory and Critical Care Medicine,The First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
出处
《哈尔滨医科大学学报》
CAS
2023年第5期562-566,共5页
Journal of Harbin Medical University
基金
黑龙江省级大学生创新创业训练计划项目(S202210226063)
